Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00457795 · ClinicalTrials.gov registry record · Phase 4
24-hour IOP-lowering Effect of Brimonidine 0.1%
A Phase 4 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 4
- Development phase
- 15
- Enrollment target
NCT00457795 is a Phase 4 study that has completed, run by Allergan. The registered enrollment target is 15 participants.
The verdict
NCT00457795, a Phase 4 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
Interventions
- DRUG brimonidine 0.1% (Alphagan® P)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2006-12 |
| Est. Completion | 2009-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00457795
The ClinicalTrials.gov registry entry for NCT00457795 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which brimonidine 0.1% (Alphagan® P) is the first listed.
NCT00457795 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00457795 about?
NCT00457795 is a clinical study titled "24-hour IOP-lowering Effect of Brimonidine 0.1%". This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension
What is the current status of trial NCT00457795?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 15 participants. The study started on 2006-12. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00457795?
The interventions under investigation include: brimonidine 0.1% (Alphagan® P) (DRUG).
Who is sponsoring clinical trial NCT00457795?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.